Scientists finally uncover why statins cause muscle pain

Statins save lives, but muscle symptoms push too many people off therapy. New research from Columbia University suggests a concrete biological reason: some statins can latch onto a muscle protein and trigger a tiny calcium leak that disrupts normal muscle function.

That matters because heart disease is largely preventable, and keeping people on effective therapies is a critical part of building a future free of heart disease.

Source: Columbia University Irving Medical Center. The study was published in the Journal of Clinical Investigation.

What the study shows

Using cryo-electron microscopy, the team visualized how simvastatin can bind to two sites on the ryanodine receptor, a key muscle protein that controls calcium flow. That binding appears to open a channel that lets calcium leak into parts of the cell where it should not be.

According to the authors, the excess calcium may weaken muscle fibers directly or activate enzymes that gradually break down muscle tissue, offering a long-sought explanation for statin-related aches in some patients.

Why it matters for patients

• It validates patient experiences with a tangible mechanism, not just anecdote.
• It explains why symptoms vary: not every statin, and not every body, reacts the same way.
• It opens the door to safer statins or companion therapies that protect muscle while preserving cholesterol control.

Practical takeaways

• Do not stop a statin without talking to your clinician; the cardiovascular benefits are substantial.
• If you develop muscle symptoms, ask about alternative statins, dose adjustments, or dosing schedules.
• Track timing, severity, and triggers of symptoms to help your clinician distinguish statin effects from other causes.
• Ask whether other risk factors (thyroid, vitamin D, intense exercise) could be contributing to muscle pain.

Our analysis at Veevo

This is exactly why precision heart health matters. Statins are not one-size-fits-all. As we build personalized prevention, we need to identify who benefits most, who is at risk for side effects, and which therapy profile fits each person.

Study details and disclosures

The study was published Dec. 15 in the Journal of Clinical Investigation as "Structural basis for simvastatin-induced skeletal muscle weakness associated with RyR1 T4709M mutation." The authors include researchers from Columbia University and the University of Rochester.

Funding came from multiple NIH grants. The authors disclosed relevant patents and equity interests related to ryanodine receptor-targeting compounds.